NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced.
Laidlaw Venture Partners Portfolio Company Algorithm Sciences, Inc. Closes $5.0 Million Series B Financing Round
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $5.0 million Series B financing round for its portfolio company Algorithm Sciences, Inc.
Algorithm Sciences is a development stage biopharmaceutical company focused on optimizing treatment for rare cardiovascular diseases (CVDs). Despite the fact that many drugs have been approved for treatment of various CVDs, it is recognized in the medical community that treatment could be significantly improved. Through the company’s lead product, we believe Algorithm Sciences has the tools and technologies to deliver therapy to achieve improved outcomes.
Share:
NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) Laidlaw Venture Partners ( LVP ), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series A financing round for its portfolio company AerWave.
AerWave offers an interventional approach to treat Asthma, COPD and advanced lung disease, which addresses a significant unmet medical need. It is targeting the addressable COPD market made up of 4 million patients in the US, and the addressable Asthma market of 2.5 million patients in the US. The Company has broad intellectual property protection in place and a seasoned, experienced executive team with a track record of value creation.